Win-Partners Co

Win-Partners Co Rule of 40

The Rule of 40 of Win-Partners Co (3183.T) as of Nov 2, 2026 is 14.37 %. In the previous year, Rule of 40 was 9.09 % — a change of 58.14% (higher).

Rule of 40

14.37 %

YoY

58.14%

Last updated:

Rule of 40 of Win-Partners Co is 2026 14.37 % . Rule of 40 of Win-Partners Co was 2025 9.09 % . It decreases by 58.14% higher compared to the previous year.

The Win-Partners Co Rule of 40 history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Rule of 40
Date
Rule of 40
Jan 1, 2019
15.72 JPY
Jan 1, 2020
-3.40 JPY
Jan 1, 2021
-0.11 JPY
Jan 1, 2022
11.03 JPY
Jan 1, 2023
10.21 JPY
Jan 1, 2024
12.17 JPY
Jan 1, 2025
9.09 JPY
Jan 1, 2026
14.37 JPY
The Win-Partners Co Rule of 40 history
YEARRule of 40YoY
14.37 %+58.14%
9.09 %-25.33%
12.17 %+19.25%
10.21 %-7.46%
11.03 %-10,125.66%
-0.11 %-96.77%
-3.40 %-121.63%
15.72 %+14.07%
13.79 %+15.19%
11.97 %-4.84%
12.58 %+90.26%
6.61 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Win-Partners Co Stock analysis

What does Win-Partners Co do? WIN-Partners Co., Ltd. generates revenue through the management of its group of companies specializing in medical device sales. The company offers catheters for ischemic heart disease, pacemakers for cardiac rhythm management, artificial blood vessels for cardiovascular surgery, and embolization coils for peripheral vascular disease and brain surgery. Additionally, it provides large-scale medical equipment including computed tomography (CT) systems for radiology departments and operating rooms. Its primary customers are healthcare institutions requiring advanced medical technology solutions. The company's product portfolio targets specific medical specialties, with catheters, pacemakers, and artificial blood vessels serving cardiovascular applications. Embolization coils address vascular and neurological procedures, while CT equipment supports diagnostic imaging needs across various hospital departments. These offerings are distributed through the company's managed group of medical device sales entities. WIN-Partners focuses on high-value medical devices that require specialized sales channels and technical support. Its business model centers on managing a network of companies that handle the distribution and sales of these medical technologies to hospitals and clinics. The firm's revenue streams are derived from the sale of these specialized medical devices and equipment to healthcare providers in Japan and potentially international markets. Win-Partners Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Win-Partners Co stock

Rule of 40 of Win-Partners Co is 14.37 % in 2026.

On Eulerpool you can find the complete historical development of Rule of 40 Win-Partners Co since 2006 – with annual values, charts, and detailed analysis.

The Rule of 40 states that a company's revenue growth rate plus profit margin should exceed 40%. It is widely used to evaluate SaaS and high-growth companies.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Quality — Win-Partners Co

All Key Metrics — Win-Partners Co